# The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 113

Extent: E+W+S+N.I.

For regulation 145 (amendment of regulation 186 (reporting obligations on the licensing authority)) substitute—
“145 In regulation 186—
(a) in paragraph (1), for sub-paragraphs (d) and (e) substitute—
“(d) submit reports of serious suspected adverse reactions in Northern Ireland that it has recorded under regulation 185 in relation to—
(i) a UKMA(NI),
(ii) a UKMA(UK),
(iii) a THR(NI),
(iv) a THR(UK), or
(v) an Article 126a authorisation,
to the EMA before the end of the period of 15 days beginning on the day following the day on which the report was received; and
(e) submit reports of non-serious suspected adverse reactions in Northern Ireland that it has recorded under regulation 185 in relation to—
(i) a UKMA(NI),
(ii) a UKMA(UK),
(iii) a THR(NI),
(iv) a THR(UK), or
(v) an Article 126a authorisation,
to the EMA before the end of the period of 90 days beginning on the day following the day on which the report was received.”;
(b) omit paragraph (4).”.

---
Source: https://www.legislation.gov.uk/uksi/2020/1488/schedule/2/paragraph/113 (the official version)
Page: https://openlegislation.uk/human-medicines-amendment-etc-eu-exit-regulations-2020/schedule-2/paragraph-113
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.